Yahoo Finance Trending tickers: Apple | Samsung | GSK | Jupiter
The latest investor updates on stocks that are trending on Tuesday
Apple (AAPL)
Apple will release its new Vision Pro headset in the US on 2 February, with pre-orders opening on 19 January, in what CEO Tim Cook has described as the "dawn of spatial computing".
Apple is yet to announce any kind of release schedule across the rest of the world.
Shoppers can pick up the headset, which “starts at” $3,499 with 256GB of storage, at US Apple Store locations and the online store. Apple is yet to give full information on what the lowest price means.
Read more: LIVE: FTSE 100 higher amid Wall Street tech rally
The Vision Pro is a full iOS-ready computer in VR headset form, with an ability to blend the real world and virtual objects together in-headset.
Samsung (005930.KS)
Samsung posted its sixth consecutive quarter of falling operating profit amid a slowdown in demand for consumer electronics.
The South Korea-based company reported a 35% fall in operating income to 2.8 trillion won (£1.76bn/$2.13) in the October-December quarter. Revenue slid 4.9% to 67 trillion won. For all of 2023, Samsung reported its slimmest operating profit in 15 years.
Demand for electronic gadgets and the memory chips that go in them ramped up during Covid lockdowns as consumers bought devices to use at home.
Read more: Stocks that are trending today
However, semiconductor prices have slumped due to massive oversupply as demand for electrical devices was hit by the global economic downturn.
“The [semiconductor] industry cycle is stabilising faster than expected thanks to supply adjustments,” Roko Kim, an analyst at Hana Financial Investment told the FT.
GSK (GSK.L)
Pharmaceutical company GSK said it had bought Aiolos Bio for an upfront consideration of $1bn, with the potential for an additional $400m.
The treatment, named AIO-001, is ready to enter phase II clinical development for the treatment of adult patients with asthma.
The Anglo-Swedish corporation said the acquisition would give it access to a potentially “best in class” new medicine, which could redefine the standard of care with dosing every six months.
Aiolos launched just three months ago, after raising $245m in financing from investors including Atlas Venture and Bain, but its treatment is ready to enter mid-stage, phase II trials, according to GSK.
GSK chief scientific officer Tony Wood said: “Adding AIO-001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio, including to the 40% of severe asthma patients with low T2 inflammation where treatment options are still needed.”
Jupiter (JUP.L)
Shares in the UK-based asset manager plunged 17% after the fund house warned it is anticipating worse outflows than previously expected in 2023.
Investors pulled £2.2bn from the asset manager last year, the sixth consecutive year of net outflows.
The fund firm blamed "a delay" in some institutional mandates and weaker retail sentiment in October and November for the increased full year net outflows, after forecasting at the start of last year that they would be "modest".
Read more: Tackling the myths holding back your pension planning
The group also announced that Ben Whitmore, manager of several of its most important funds such as Jupiter UK Special Situations Fund, Jupiter Income Trust, Jupiter Global Value Unit Trust, and Jupiter Global Value SICAV, will depart in July.
Whitmore will be replaced by Alex Savvides, who will join from JO Hambro Capital Management to take over the special situations fund.
Watch: Apple Vision Pro headset first look: Impressive, immersive and heavy
Download the Yahoo Finance app, available for Apple and Android.
